Ananda Pharma has taken one other main step ahead in bringing its flagship MRX1 CBD oral resolution to market.
Right this moment (June 17), Ananda revealed the total scientific examine report from its Section I pharmacokinetic trial of its proprietary MRX1 compound, confirming all aims have been met, a clear security profile throughout 20 individuals, and assist for the FDA’s 505(b)(2) growth pathway.
Its publication formally closes out the preparatory part of the MRX1 programme, with Section II dosing throughout each trials on monitor for the second half of 2026.
Clear knowledge
Ananda first dosed individuals with MRX1 as a part of the Section I trials in Australia in July 2025, via a trial carried out in partnership with scientific analysis organisation Southern Star Analysis. Preliminary security knowledge revealed in November 2025 confirmed no severe hostile occasions, and this remaining report expands on the findings.
Throughout 20 individuals who acquired at the very least one dose, all treatment-emergent hostile occasions have been delicate (Grade 1). No reasonable or extreme occasions, severe hostile occasions, or discontinuations have been recorded.
There have been no deaths and no clinically vital modifications in liver perform, a security sign regulators study carefully when evaluating high-dose CBD therapies. Ananda described the profile as per the established security document of CBD-based medicines.
The trial assessed MRX1 at 2.5 mg/kg and seven.5 mg/kg, administered twice day by day over six days, with fed and fasted circumstances evaluated on the decrease dose.
The pharmacokinetic knowledge gathered will assist regulatory submissions within the UK, US and EU, and Ananda has confirmed the finished report underpins its software via the FDA 505(b)(2) pathway, which permits builders to construct on current security knowledge from permitted medicine fairly than pursuing a full de-novo submission.
Ananda’s CEO, Melissa Sturgess, stated in a press launch: “This is a vital achievement for Ananda and places us in a powerful place as we transfer into dosing sufferers within the forthcoming ENDOCAN and ACTION Section 2 scientific trials.”
The Section I trial was carried out via the corporate’s native subsidiary, making the expenditure eligible for Australia’s 43.5% refundable R&D tax rebate. Ananda acquired an preliminary compensation of AUD340,166 in November 2025, with an extra AUD500,000 anticipated within the third quarter of 2026, non-dilutive funding that extends the corporate’s runway with out additional fairness issuance.
READ MORE…
Past MRX1
MRX1 is one among three drug candidates Ananda has developed, although it’s now the only focus of the corporate’s scientific programme. The 2 different formulations, MRX2 and MRX2T, have been developed for government-backed epilepsy trials at College School London and Nice Ormond Road Hospital, trials introduced in October 2024 and co-funded by the NIHR and NHS.
In September 2025, Ananda was formally notified by UCL that its formulation was not required, after the corporate’s manufacturing contractor failed to fulfill its obligations. The trials are anticipated to proceed with another provider, however Ananda has no additional involvement.
The pivot leaves MRX1 carrying the total weight of the corporate’s scientific ambitions, and provides further significance to this newest milestone as a gateway to Section II scientific trials.
Ananda is now within the remaining phases of preparation for 2 randomised managed trials on the College of Edinburgh, each funded by the NHS and authorities our bodies.
The ENDOCAN trial, which acquired MHRA and NHS Well being Analysis Authority approval to start dosing in March 2026, will consider MRX1 in as much as 100 ladies with endometriosis-associated ache throughout NHS Lothian and NHS Grampian, funded by the Chief Scientist Workplace.
The ACTION trial, funded by the Nationwide Institute for Well being and Care Analysis, is investigating MRX1 for chemotherapy-induced peripheral neuropathy. Each trials have the College of Edinburgh‘s analysis crew as principal investigators, with Dr Lucy Whitaker main ENDOCAN alongside Professors Andrew Horne and Phillipa Saunders. Dosing throughout each programmes stays on monitor for the second half of 2026.